Clinical Manifestations of Benign Prostatic Hyperplasia (BPH): Early Detection Protocol

The Hidden Physiology of BPH

Benign Prostatic Hyperplasia starts silently. The prostate gland, located at the base of the bladder, begins to undergo hyperplasia (cellular multiplication) driven by hormonal imbalances (DHT).

This enlargement exerts mechanical pressure on the urethra, leading to clinical voiding dysfunction.

Diagnostic indicators (Nocturia & Flow)

• Nocturia: Waking 2+ times nightly indicates incomplete bladder emptying due to urethral compression.
• Urine Retention: The inability to fully void creates a bacterial reservoir, increasing infection risk.
• Flow Hesitancy: A delayed start to urination signals significant obstruction.

The “Watchful Waiting” Fallacy

Standard care often suggests “watching” mild symptoms. However, mechanical obstruction inevitably worsens without intervention. Early modulation of inflammation is critical to preserving long-term function.

Bio-Active Intervention: ProstaVive

ProstaVive utilizes a potent blend of phytosterols and botanical anti-inflammatories designed to reduce prostatic edema (swelling) and inhibit the 5-alpha-reductase enzyme responsible for DHT conversion.